Research & Literature

Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms.

Paulin F, Doyle TJ, Fletcher EA, et al.

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2015; (67(5)):280-6.

Smoking and Subclinical ILD in RA versus the Multi-Ethnic Study of Atherosclerosis.

Johnson C, Giles JT, Bathon J, et al.

PloS one 2016; (11(4)):e0153024 doi:10.1371/journal.pone.0153024.

Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease.

Ota M, Iwasaki Y, Harada H, et al.

Modern rheumatology 2017; (27(1)):22-28 doi:10.3109/14397595.2016.1173816.

Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes.

Nurmi HM, Purokivi MK, Kärkkäinen MS, et al.

BMC pulmonary medicine 2016; (16(1)):107 doi:10.1186/s12890-016-0269-2.

Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?

Nurmi HM, Purokivi MK, Kärkkäinen MS, et al.

BMC pulmonary medicine 2017; (17(1)):16 doi:10.1186/s12890-016-0358-2.

Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis.

Juge PA, Borie R, Kannengiesser C, et al.

The European respiratory journal 2017; (49(5)) doi:10.1183/13993003.02314-2016.

Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis.

Spagnolo P, Wuyts W

Current opinion in pulmonary medicine 2017; (23(5)):411-417 doi:10.1097/MCP.0000000000000405.

Acute Exacerbation in Interstitial Lung Disease.

Leuschner G, Behr J

Frontiers in medicine 2017; (4()):176 doi:10.3389/fmed.2017.00176.

Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis.

Samara KD, Trachalaki A, Tsitoura E, et al.

Respiratory research 2017; (18(1)):218 doi:10.1186/s12931-017-0692-9.

Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease.

Nurmi HM, Kettunen HP, Suoranta SK, et al.

Respiratory medicine 2018; (134()):24-30 doi:10.1016/j.rmed.2017.11.013.

Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population.

Fu Q, Wang L, Li L, et al.

Clinical rheumatology 2019; (38(4)):1109-1116 doi:10.1007/s10067-018-4382-x.

Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis.

Singh N, Varghese J, England BR, et al.

Seminars in arthritis and rheumatism 2019; (49(3)):358-365 doi:10.1016/j.semarthrit.2019.04.005.

A preliminary study of lung abnormalities on HRCT in patients of rheumatoid arthritis-associated interstitial lung disease with progressive fibrosis.

Li L, Gao S, Fu Q, et al.

Clinical rheumatology 2019; (38(11)):3169-3178 doi:10.1007/s10067-019-04673-4.

High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalities.

Salaffi F, Carotti M, Di Carlo M, et al.

Medicine 2019; (98(38)):e17088 doi:10.1097/MD.0000000000017088.

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Characteristics and Predictors of Mortality.

Hyldgaard C, Ellingsen T, Hilberg O, Bendstrup E

Respiration; international review of thoracic diseases 2019; (98(5)):455-460 doi:10.1159/000502551.

Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria.

Yamakawa H, Sato S, Tsumiyama E, et al.

Journal of thoracic disease 2019; (11(12)):5247-5257 doi:10.21037/jtd.2019.11.73.

Management issues in rheumatoid arthritis-associated interstitial lung disease.

England BR, Hershberger D

Current opinion in rheumatology 2020; (32(3)):255-263 doi:10.1097/BOR.0000000000000703.

Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?

Cassone G, Sebastiani M, Vacchi C, et al.

Respiratory medicine case reports 2020; (30()):101051 doi:10.1016/j.rmcr.2020.101051.

Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality.

Hida T, Nishino M, Hino T, et al.

European journal of radiology 2020; (129()):109073 doi:10.1016/j.ejrad.2020.109073.

Prevalence of viral infection in acute exacerbation of interstitial lung diseases in Japan.

On R, Matsumoto T, Kushima H, et al.

Respiratory investigation 2020; (58(6)):473-478 doi:10.1016/j.resinv.2020.06.006.

Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.

Miyashita K, Kono M, Saito G, et al.

The clinical respiratory journal 2021; (15(3)):336-344 doi:10.1111/crj.13304.

A Case of Rheumatoid Arthritis-Associated Interstitial Lung Disease - An Unfortunate Complication of Untreated Rheumatoid Arthritis!

Ruggiero RA, Iqbal QZ, Zia Z, et al.

Cureus 2020; (12(10)):e11074 doi:10.7759/cureus.11074.

Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment.

Huang S, Kronzer VL, Dellaripa PF, et al.

Current treatment options in rheumatology 2020; (6(4)):337-353 doi:10.1007/s40674-020-00160-z.

Rheumatoid arthritis related interstitial lung disease.

Manfredi A, Cassone G, Luppi F, et al.

Expert review of clinical immunology 2021; (17(5)):485-497 doi:10.1080/1744666X.2021.1905524.

Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.

Schmid U, Weber B, Sarr C, Freiwald M

BMC pulmonary medicine 2021; (21(1)):244 doi:10.1186/s12890-021-01598-0.

The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases.

Wang Y, Chen S, Zheng S, et al.

Arthritis research & therapy 2021; (23(1)):212 doi:10.1186/s13075-021-02586-9.

A Closer Look at the Role of Anti-CCP Antibodies in the Pathogenesis of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Bronchiectasis.

Khan T, Jose RJ, Renzoni EA, Mouyis M

Rheumatology and therapy 2021; (8(4)):1463-1475 doi:10.1007/s40744-021-00362-4.

Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD).

Yamakawa H, Ogura T, Kameda H, et al.

Journal of clinical medicine 2021; (10(17)) doi:10.3390/jcm10173806.

Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.

Qiu M, Jiang J, Nian X, et al.

Respiratory research 2021; (22(1)):264 doi:10.1186/s12931-021-01856-z.

Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort.

Samhouri BF, Vassallo R, Achenbach SJ, et al.

Arthritis care & research 2022; (74(12)):2042-2049 doi:10.1002/acr.24856.

The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease.

Abu Qubo A, Capaccione KM, Bernstein EJ, et al.

Frontiers in medicine 2021; (8()):679051 doi:10.3389/fmed.2021.679051.

Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model.

Hozumi H, Kono M, Hasegawa H, et al.

Respiratory research 2022; (23(1)):57 doi:10.1186/s12931-022-01978-y.

[Latest news on RA-ILD].

Schreiber T, Hagmeyer L, Kofler DM, et al.

Pneumologie (Stuttgart, Germany) 2022; (76(9)):614-621 doi:10.1055/a-1895-9360.

Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.

Matson SM, Baqir M, Moua T, et al.

Chest 2023; (163(4)):861-869 doi:10.1016/j.chest.2022.11.035.

Risk factors for rheumatoid arthritis-associated interstitial lung disease: a retrospective study.

Ben Tekaya A, Mokaddem S, Athimini S, et al.

Multidisciplinary respiratory medicine 2022; (17()):877 doi:10.4081/mrm.2022.877.

Diffuse lung involvement in rheumatoid arthritis: a respiratory physician's perspective.

Huang H, Chen R, Shao C, et al.

Chinese medical journal 2023; (136(3)):280-286 doi:10.1097/CM9.0000000000002577.

Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial.

Matteson EL, Aringer M, Burmester GR, et al.

Clinical rheumatology 2023; (42(9)):2311-2319 doi:10.1007/s10067-023-06623-7.

Factors associated with interstitial lung disease in patients with rheumatoid arthritis: A systematic review and meta-analysis.

Zhang M, Yin J, Zhang X

PloS one 2023; (18(6)):e0286191 doi:10.1371/journal.pone.0286191.

Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.

Xie M, Zhu C, Ye Y

BMC pulmonary medicine 2023; (23(1)):255 doi:10.1186/s12890-023-02532-2.

Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis.

Atienza-Mateo B, Fernández-Díaz C, Vicente-Rabaneda EF, et al.

European journal of internal medicine 2024; (119()):118-124 doi:10.1016/j.ejim.2023.08.025.

Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian Study.

Sebastiani M, Venerito V, Laurino E, et al.

Journal of clinical medicine 2023; (12(22)) doi:10.3390/jcm12227041.

PM10 increases mortality risk in rheumatoid arthritis-associated interstitial lung disease.

Kim SH, Kim SY, Yoon HY, Song JW

RMD open 2024; (10(1)) doi:10.1136/rmdopen-2023-003680.

Multidimensional biomarker approach integrating tumor markers, inflammatory indicators, and disease activity indicators may improve prediction of rheumatoid arthritis-associated interstitial lung disease.

Wan J, Yu Z, Cao X, et al.

Clinical rheumatology 2024; (43(6)):1855-1863 doi:10.1007/s10067-024-06984-7.

Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease.

Venkat RK, Hayashi K, Juge PA, et al.

Clinical rheumatology 2024; (43(8)):2453-2466 doi:10.1007/s10067-024-07028-w.

Identification and management of interstitial lung disease associated with systemic sclerosis (SSc-ILD), rheumatoid arthritis (RA-ILD), and polymyositis/dermatomyositis (PM/DM-ILD): development of expert consensus-based clinical algorithms.

Kondoh Y, Bando M, Kawahito Y, et al.

Expert review of respiratory medicine 2024; (18(6)):447-456 doi:10.1080/17476348.2024.2374910.

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

Johnson SR, Bernstein EJ, Bolster MB, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2024; (76(8)):1201-1213 doi:10.1002/art.42860.

Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances.

Naqvi M, Hannah J, Lawrence A, et al.

Expert review of respiratory medicine 2024; (18(6)):397-407 doi:10.1080/17476348.2024.2375420.

Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-Associated Interstitial Lung Disease Subtypes.

McDermott GC, Hayashi K, Juge PA, et al.

Arthritis care & research 2025; (77(2)):185-194 doi:10.1002/acr.25432.

A Systematic Review of the Key Predictors of Progression and Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Groseanu L, Niță C

Diagnostics (Basel, Switzerland) 2024; (14(17)) doi:10.3390/diagnostics14171890.

Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People.

Mueller KT, Saavedra AA, O'Keeffe LA, Sparks JA

Drugs & aging 2025; (42(2)):81-94 doi:10.1007/s40266-024-01175-0.

Serum Biomarkers of Pulmonary Damage and Risk for Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Chang SH, Park YB, McDermott GC, et al.

The Journal of rheumatology 2025; (52(4)):323-333 doi:10.3899/jrheum.2024-0713.

Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline.

Saavedra AA, Mueller KT, Kowalski EN, et al.

Current treatment options in rheumatology 2024; (10(4)):43-60 doi:10.1007/s40674-024-00217-3.

Lung ultrasound outperforms symptom-based screening to detect interstitial lung disease associated with rheumatoid arthritis.

Vermant M, Kalkanis A, Jacob J, et al.

RMD open 2025; (11(1)) doi:10.1136/rmdopen-2024-005283.

Prevalence and clinical significance of anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis-associated interstitial lung disease.

Huang Z, Wu T, Lu R, et al.

BMC pulmonary medicine 2025; (25(1)):177 doi:10.1186/s12890-025-03644-7.

Development of a prediction model for progression of rheumatoid arthritis-associated interstitial lung disease using serologic and clinical factors: The prospective KORAIL cohort.

Chang SH, Paudel ML, McDermott GC, et al.

Seminars in arthritis and rheumatism 2025; (73()):152729 doi:10.1016/j.semarthrit.2025.152729.

Procalcitonin in acute exacerbation of interstitial lung disease: A systematic review of current evidence.

Srivali N, De Giacomi F

Heart & lung : the journal of critical care 2025; (73()):221-227 doi:10.1016/j.hrtlng.2025.05.014.

Heterogeneity of Rheumatoid Arthritis-Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes.

England BR, Yang Y, Roul P, et al.

Arthritis care & research 2026; (78(2)):249-258 doi:10.1002/acr.25620.

Are we screening effectively? A systematic review and meta-analysis of proposed risk factors for rheumatoid arthritis-associated interstitial lung disease screening.

Ikdahl E, Mangseth H

Scandinavian journal of rheumatology 2026; (55(1)):59-67 doi:10.1080/03009742.2025.2538946.

Short telomere length is associated with accelerated lung disease progression in rheumatoid arthritis-associated interstitial lung disease.

El Husseini K, Lee JS, Juge PA, et al.

The European respiratory journal 2025; (66(6)) doi:10.1183/13993003.00587-2025.

Acute Exacerbation of Interstitial Lung Disease: Early Diagnosis and Treatment.

León-Román F, Martínez-Besteiro E, Iturbe D, et al.

Medicina (Kaunas, Lithuania) 2025; (61(12)) doi:10.3390/medicina61122097.

Functional, radiological and survival outcomes in rheumatoid arthritis-associated interstitial lung disease: 24-month results from the BERTHA prospective cohort.

Kawano-Dourado L, Bonfiglioli K, Ribeiro ACM, et al.

BMJ open respiratory research 2026; (13(1)) doi:10.1136/bmjresp-2025-003973.

Rheumatoid arthritis-associated interstitial lung disease: A review.

David M, Dieude P, Juge PA, et al.

Respiratory medicine and research 2026; (89()):101260 doi:10.1016/j.resmer.2026.101260.

Validation of screening criteria for interstitial lung disease in rheumatoid arthritis in routine clinical practice: the VAR-EPIDSER study.

Mena-Vázquez N, Domínguez-Álvaro M, Bonilla Hernán MG, et al.

RMD open 2026; (12(2)) doi:10.1136/rmdopen-2026-006934.

Rheumatoid Arthritis-Associated Interstitial Lung Disease Presenting With Raynaud's Phenomenon: A Case Report.

Ghule P, Sontakke A, Ali S, et al.

Cureus 2026; (18(4)):e107697 doi:10.7759/cureus.107697.

Rheumatoid arthritis-associated interstitial lung disease: Pathogenesis, risk stratification, and management.

Gao R, Liu S, Song L

Respiratory medicine 2026; (261()):109066 doi:10.1016/j.rmed.2026.109066.